![]() It also enables business leaders to better understand the types of syn-bio firms that have emerged either as potential rivals or partners and to anticipate the ones that will do so in the future. Syn-bio’s swift evolution presents a challenge for incumbent companies’ CEOs, many of whose industries are likely to be disrupted.Ī syn-bio industry stack provides a deeper understanding of the context in which incumbents have to frame strategies. Despite the growing stagflationary pressures and uncertainty in the world economy, which is slowing venture funding, many big bets-such as Moderna’s partnership with the UK government to set up a $1.2-billion mRNA vaccine manufacturing facility by 2025-have been announced recently. Notes: 1 4Q 2021 Synthetic Biology Venture Investment Report, Built with Biology, Febru. A recent report by SynBioBeta, a global industry organization, estimated that syn-bio startups raised nearly $18 billion in 2021-almost as much as they did in the 11 years between 20Ĭombined 1 1 4Q 2021 Synthetic Biology Venture Investment Report, Built with Biology, Febru. Naturally, investors have realized the lucrative prospects of investing in syn-bio startups. An industry of science-based startups has sprung up globally, each trying to alter conventional products and processes to transform the world sustainably. ![]() In the next ten years, syn-bio could affect sectors that will account for as much as $30 trillion, or nearly a third, of global GDP, according to our studies, especially in sectors such as chemicals, cosmetics, dyes, food grains, foods, leather, pharmaceuticals, and textiles. ![]() As companies step up the use of syn-bio to create novel products, the technology is helping to develop new raw materials, new products, and new processes. By using AI, syn-bio scientists have been able to develop a better understanding of the relationships between biomolecular structures and their functions, enabling them to design novel biomolecules.īecause of advances in precision fermentation, syn-bio is moving out of labs into the world of business. A 2019 Nature paper projected that by 2030, new syn-bio technologies are likely to become available to even organizations with low technical skills and limited financial resources.Īs syn-bio becomes more granular, its convergence with digital technologies, such as AI, has provided a fillip to its evolution. Moreover, the new technologies are becoming widely available. The cost of writing DNA too has shrunk, from about $4 in 2004 to between 5 and 10 cents per base pair in 2021. As a result, the cost of reading DNA has fallen by over 300% since 2007, outpacing even Moore’s Law of computing power. Cell-free biology too has advanced, allowing companies to use metabolic cell processes that don’t need live cells and make testing faster. Technological advances-such as nanoliter scale screening and microfluidic technologies-have helped create new DNA combinations, reduced DNA-editing costs, and increased the lengths of DNA strands that can be built. The rise of new syn-bio tools and techniques has transformed the field.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |